M

Middle East Pharmaceutical Industries Company SJSC
SAU:4016

Watchlist Manager
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Watchlist
Price: 121.2 SAR 1.68%
Market Cap: 2.4B SAR

Intrinsic Value

The intrinsic value of one Middle East Pharmaceutical Industries Company SJSC stock under the Base Case scenario is 93.55 SAR. Compared to the current market price of 121.2 SAR, Middle East Pharmaceutical Industries Company SJSC is Overvalued by 23%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
93.55 SAR
Overvaluation 23%
Intrinsic Value
Price
M
Worst Case
Base Case
Best Case

Valuation History
Middle East Pharmaceutical Industries Company SJSC

What is Valuation History?
Ask AI Assistant
What other research platforms think about Middle East Pharmaceutical Industries Company SJSC?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is Middle East Pharmaceutical Industries Company SJSC valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Middle East Pharmaceutical Industries Company SJSC.

Explain Valuation
Compare Middle East Pharmaceutical Industries Company SJSC to

Fundamental Analysis

Middle East Pharmaceutical Industries Company SJSC
SAU:4016
SA
Pharmaceuticals
Market Cap
2.4B SAR
IPO
Feb 27, 2024
SA
Pharmaceuticals
Market Cap
2.4B SAR
IPO
Feb 27, 2024
Price
Middle East Pharmaceutical Industries Company SJSC
Company Overview
Loading...
Economic Moat
Loading...
Contacts
Loading...
How do you feel about Middle East Pharmaceutical Industries Company SJSC?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Middle East Pharmaceutical Industries Company SJSC

Balance Sheet Decomposition
Middle East Pharmaceutical Industries Company SJSC

Current Assets 380.5m
Cash & Short-Term Investments 19.4m
Receivables 230.8m
Other Current Assets 130.4m
Non-Current Assets 185.1m
PP&E 125.5m
Intangibles 59.6m
Current Liabilities 143.7m
Accounts Payable 51.6m
Accrued Liabilities 39.7m
Short-Term Debt 36.1m
Other Current Liabilities 16.4m
Non-Current Liabilities 50.5m
Long-Term Debt 21.5m
Other Non-Current Liabilities 29m
Efficiency

Free Cash Flow Analysis
Middle East Pharmaceutical Industries Company SJSC

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Middle East Pharmaceutical Industries Company SJSC

Revenue
459m SAR
Cost of Revenue
-176.8m SAR
Gross Profit
282.2m SAR
Operating Expenses
-173.3m SAR
Operating Income
108.8m SAR
Other Expenses
-11.5m SAR
Net Income
97.3m SAR
Fundamental Scores

Profitability Score
Profitability Due Diligence

Middle East Pharmaceutical Industries Company SJSC's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

Positive 3Y Average ROIC
Exceptional 3Y Average ROE
Exceptional ROE
Positive ROIC
63/100
Profitability
Score

Middle East Pharmaceutical Industries Company SJSC's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Middle East Pharmaceutical Industries Company SJSC's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
83/100
Solvency
Score

Middle East Pharmaceutical Industries Company SJSC's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Middle East Pharmaceutical Industries Company SJSC

Wall Street analysts forecast Middle East Pharmaceutical Industries Company SJSC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Middle East Pharmaceutical Industries Company SJSC is 135.66 SAR with a low forecast of 134.33 SAR and a high forecast of 139.65 SAR.

Lowest
Price Target
134.33 SAR
11% Upside
Average
Price Target
135.66 SAR
12% Upside
Highest
Price Target
139.65 SAR
15% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Middle East Pharmaceutical Industries Company SJSC
does not pay dividends
Shareholder Yield

Current shareholder yield for Middle East Pharmaceutical Industries Company SJSC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one Middle East Pharmaceutical Industries Company SJSC stock?

The intrinsic value of one Middle East Pharmaceutical Industries Company SJSC stock under the Base Case scenario is 93.55 SAR.

Is Middle East Pharmaceutical Industries Company SJSC stock undervalued or overvalued?

Compared to the current market price of 121.2 SAR, Middle East Pharmaceutical Industries Company SJSC is Overvalued by 23%.

Back to Top